Achillion to Present at the Barclays Global Healthcare Conference
March 08 2019 - 6:00AM
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage
biopharmaceutical company dedicated to transforming the lives of
patients and families affected by complement-mediated diseases,
today announced that Joseph Truitt, President and Chief Executive
Officer and Brian Di Donato, Chief Financial Officer of Achillion
will present at the Barclays Global Healthcare Conference on
Thursday, March 14, 2019, at 10:15 a.m. ET at the Loews Miami Beach
Hotel in Miami, FL.
The live audio and subsequent archived webcasts
of the Company's presentation will be accessible from the Company's
investor relations website, http://ir.achillion.com. The audio
recording will be archived for 60 days following the live
presentation. Please connect to Achillion's website several minutes
prior to the start of the presentation to ensure adequate time for
any software downloads that may be necessary.
About Achillion
PharmaceuticalsAchillion Pharmaceuticals,
Inc. (NASDAQ:ACHN) is a clinical-stage biopharmaceutical
company focused on advancing its oral, small molecule,
complement system inhibitors into late-stage development and
commercialization. Each of the product candidates in the
Company’s portfolio was discovered in its laboratories and is
wholly owned. Achillion is initially focusing its drug
development activities on alternative pathway-mediated diseases
where there are no approved therapies or where existing therapies
are inadequate for patients. Initial indications being evaluated
for its compounds include paroxysmal nocturnal hemoglobinuria
(PNH), C3 glomerulopathy (C3G), and immune complex
membranoproliferative glomerulonephritis (IC-MPGN). To advance its
investigational drugs into phase 3 and commercialization, the
Company plans to work closely with key stakeholders including
patients, payors, regulators and healthcare professionals.
More information is available at http://www.achillion.com.
Investors:Brian Di DonatoChief Financial
OfficerAchillion Pharmaceuticals, Inc.Tel. (215)
709-3032bdidonato@achillion.com
Media:Jon PappasMedia RelationsW2O GroupTel.
(646) 847-0303jpappas@w2ogroup.com
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Sep 2023 to Sep 2024